Inflammation-Based Index and <sup>68</sup>Ga-DOTATOC PET–Derived Uptake and Volumetric Parameters Predict Outcome in Neuroendocrine Tumor Patients Treated with <sup>90</sup>Y-DOTATOC

Elin Pauwels(KU Leuven), Christophe M. Deroose(KU Leuven), Felix M. Mottaghy(College Board), Sofie Van Binnebeek(KU Leuven), Kristiaan Nackaerts(Heidelberg University), Karin Haustermans(Radboud University Nijmegen), Vincent Vandecaveye(KU Leuven), H Vanbilloen(Society of Nuclear Medicine and Molecular Imaging), Michel Koole(KU Leuven), Kristof Baete(KU Leuven), Chris Verslype(Universitair Ziekenhuis Leuven), Eric Van Cutsem(Universitair Ziekenhuis Leuven), Paul M. Clément(Universitair Ziekenhuis Leuven)
Journal of Nuclear Medicine
December 5, 2019
10.2967/jnumed.119.236935
Cited by 44

Related Papers

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
|The Lancet|2010|7.3k
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Maintenance Olaparib for Germline <i>BRCA</i> -Mutated Metastatic Pancreatic Cancer
|New England Journal of Medicine|2019|2.2k